文献速递脑血管病

中等或远端血管闭塞急性缺血性卒中的血管内治疗:系统综述与荟萃分析

Endovascular Treatment in Acute Ischemic Stroke Due to Occlusion of Medium or Distal Vessels: A Systematic Review and Meta-Analysis.
PubMed 文献 · Neurology · 2025-08-18

该系统综述与荟萃分析纳入38项研究(3项RCT及多项观察性研究),比较血管内治疗联合最佳药物治疗与单纯药物治疗在中等或远端血管闭塞急性缺血性卒中患者中的疗效与安全性。结果显示两组3个月优良功能结局无差异,但血管内治疗增加症状性颅内出血、任何颅内出血及3个月全因死亡率。

要点

  • 血管内治疗未改善中等或远端血管闭塞卒中患者3个月功能结局。
  • 血管内治疗增加症状性颅内出血、任何颅内出血及3个月全因死亡风险。
  • 现有证据以观察性研究为主,不支持常规血管内治疗,需进一步RCT。

核心结论

  • 在中等或远端血管闭塞急性缺血性卒中患者中,血管内治疗联合最佳药物治疗相比单纯最佳药物治疗未改善功能结局,且增加出血并发症和死亡风险。
  • 这些发现不支持对该类患者常规使用血管内治疗。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Scopus和ClinicalTrials.gov至2025年2月。
  • 纳入38项研究(3项RCT、1项RCT事后分析、1项RCT个体患者数据荟萃分析、33项观察性研究)。
  • 血管内治疗组4584例(平均年龄71岁,女性46%),单纯药物治疗组5468例(平均年龄72岁,女性46%)。

主要发现

  • 3个月优良功能结局(mRS 0-1)两组相似(RR 1.02;95%CI 0.93-1.12;p=0.676;30项研究;I2=67%)。
  • 良好功能结局(mRS 0-2)无差异(RR 1.00;95%CI 0.94-1.07;p=0.933;36项研究;I2=71%)。
  • 残疾减少(mRS移位分析)无差异(共同比值比0.92;95%CI 0.80-1.07;p=0.290;10项研究;I2=20%)。
  • 血管内治疗组成功再通 pooled 率为78%(95%CI 75%-82%;25项研究;I2=82%)。
  • 血管内治疗与更高的症状性颅内出血(RR 1.54;95%CI 1.18-2.01;p=0.002;29项研究;I2=24%)、任何颅内出血(RR 1.62;95%CI 1.38-1.92;p<0.001;17项研究;I2=40%)及3个月全因死亡率(RR 1.26;95%CI 1.05-1.50;p=0.012;29项研究;I2=27%)相关。

临床怎么用

  • 对于中等或远端血管闭塞的急性缺血性卒中患者,不应常规进行血管内治疗。
  • 临床决策需个体化权衡血管内治疗的获益与出血及死亡风险。

局限性

  • 证据以观察性研究为主,随机对照试验数据有限。
  • 需要进一步RCT来细化患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Endovascular treatment (EVT) is the standard of care for acute ischemic stroke (AIS) due to large vessel occlusions, but its efficacy and safety in medium or distal vessel occlusions (MDVOs) remain uncertain. This systematic review and meta-analysis evaluated EVT plus best medical treatment (BMT) vs BMT alone in patients with MDVO-AIS. METHODS: MEDLINE, Scopus, and ClinicalTrials.gov were searched through February 2025 for randomized-controlled clinical trial (RCT) data and observational evidence comparing EVT plus BMT vs BMT alone in adults with MDVO-AIS. The primary efficacy outcome was 3-month excellent functional outcome (modified Rankin Scale [mRS]-score 0-1), while good functional outcome (mRS score 0-2), reduced disability (mRS shift analysis), and pooled rates of successful recanalization were assessed as secondary outcomes. The primary safety outcome was symptomatic intracranial hemorrhage (sICH), while any ICH, 3-month all-cause mortality, and procedure-related complications were also evaluated. RESULTS: Thirty-eight studies (3 RCTs, 1 post hoc RCT analysis, 1 RCT individual patient data meta-analysis, and 33 observational studies) were included comprising 4,584 EVT-treated patients (mean age 71 years; 46% females) and 5,468 BMT-only patients (mean age 72; 46% females). Patients receiving EVT had similar rates of 3-month excellent functional outcome compared with BMT alone (risk ratio [RR] 1.02; 95% CI 0.93-1.12; p = 0.676; 30 studies; I2 = 67%). The 2 groups did not differ in good functional outcome (RR 1.00; 95% CI 0.94-1.07; p = 0.933; 36 studies; I2 = 71%) or reduced disability (common odds ratio 0.92; 95% CI 0.80-1.07; p = 0.290; 10 studies; I2 = 20%). The pooled rate of successful recanalization in the EVT arm was 78% (95% CI 75%-82%; 25 studies; I2 = 82%). EVT was associated with higher rates of sICH (RR 1.54; 95% CI 1.18-2.01; p = 0.002; 29 studies; I2 = 24%), any ICH (RR 1.62; 95% CI 1.38-1.92; p < 0.001; 17 studies; I2 = 40%), and 3-month all-cause mortality (RR 1.26; 95% CI 1.05-1.50; p = 0.012; 29 studies; I2 = 27%). The pooled rate of procedure-related complications was 8% (95% CI 5%-12%; 8 studies; I2 = 76%). No significant subgroup differences emerged when stratified for study design or NIH Stroke Scale strata. DISCUSSION: In this comprehensive synthesis of available evidence, EVT did not improve functional outcomes compared with BMT in MDVO-AIS, while it increased the risk of hemorrhagic complications and mortality. These findings argue against the routine use of EVT for MDVO-AIS. A key limitation is the predominance of observational data, underscoring the need for further RCTs to refine patient selection. TRIAL REGISTRATION INFORMATION: The prespecified protocol of the present systematic review and meta-analysis has been registered in the International Prospective Register of Ongoing Systematic Reviews PROSPERO (registration ID: CRD42025651283).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Palaiodimou L, Safouris A, Papageorgiou NM, et al. Endovascular Treatment in Acute Ischemic Stroke Due to Occlusion of Medium or Distal Vessels: A Systematic Review and Meta-Analysis. Neurology. 2025. PMID: 40825162. doi:10.1212/WNL.0000000000214015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。